In this episode of The Onco’Zine Brief, developed in collaboration with ADC Review | Journal of Antibody-drug Conjugates (at www.ADCReview.com), Peter Hofland, Ph.D. talks with William (Bill) Newell, JD, Chief Executive Officer and a member of the Board of Directors of Sutro Biopharma (www.sutrobio.com)

Sutro is a clinical-stage drug discovery, development, and manufacturing company using precise protein engineering and rational design to advance the development of the next-generation oncology therapeutics for unmet medical needs and areas where the current standard of care is suboptimal.

To date, Sutro’s technology platform has led to the development of cytokine-based immuno-oncology therapies, antibody-drug conjugates or ADCs, vaccines, and bispecific antibodies.
In addition to Sutro’s own pipeline of novel drugs, including STRO-001, a CD74-targeting ADC currently being investigated in a Phase 1 clinical trial of patients with advanced B-cell malignancies, such as multiple myeloma and non-Hodgkin lymphoma, and STRO-002, a folate receptor alpha (FolRα)-targeting ADC, currently being investigated in a Phase 1 clinical trial of patients with ovarian and endometrial cancers, the company is also collaborating with select pharmaceutical and biotech companies to discover and develop novel, next-generation therapeutics.

Antibody-drug conjugates like STRO-001 and STRO-002, are highly targeted biopharmaceutical drugs that combine monoclonal antibodies specific to surface antigens present on particular tumor cells with highly potent anti-cancer agents linked via a chemical linker.

Today there are 10 approved ADC on the market – and many more in development. And as a result, ADCs have become a powerful class of therapeutic agents in oncology and hematology.

About The Onco'Zine Brief
The Onco'Zine Brief is distributed in the United States via PRX (Public Radio Exchange). In the United Kingdom and Europe, the program is distributed via UK Health Radio (UKHR). And the program can be downloaded via most podcasts and streaming media services, including iTunes, Spotify, TuneIn, and iHeart Radio.

For more information about The Onco'Zine Brief or how to sponsor or support this public radio broadcast and podcast, visit: https://www.patreon.com/theoncozinebrief

For more information about cancer and cancer treatments, visit our online journal Onco'Zine at www.oncozine.com

To sign up for The Onco'Zine Newsletter (open for residents of the United States only), text the word CANCER to 66866.